BioNTech - BNTX Stock Forecast, Price & News

12 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for BioNTech in the last year. There are currently 6 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BNTX shares.
View BNTX analyst ratings or view top-rated stocks.

12 brokers have issued twelve-month target prices for BioNTech's stock. Their BNTX share price forecasts range from $148.00 to $312.00. On average, they anticipate the company's stock price to reach $206.17 in the next year. This suggests a possible upside of 26.8% from the stock's current price.
View analysts price targets for BNTX or view top-rated stocks among Wall Street analysts.

BioNTech's stock was trading at $257.80 on January 1st, 2022. Since then, BNTX stock has decreased by 36.9% and is now trading at $162.63.
View the best growth stocks for 2022 here.

BioNTech saw a decline in short interest in the month of November. As of November 15th, there was short interest totaling 1,880,000 shares, a decline of 12.1% from the October 31st total of 2,140,000 shares. Based on an average daily trading volume, of 861,900 shares, the days-to-cover ratio is currently 2.2 days.
View BioNTech's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 29th 2023.
View our BNTX earnings forecast.

BioNTech SE (NASDAQ:BNTX) issued its quarterly earnings results on Monday, November, 7th. The company reported $7.04 EPS for the quarter, beating analysts' consensus estimates of $3.66 by $3.38. The firm had revenue of $3.46 billion for the quarter, compared to the consensus estimate of $1.90 billion. BioNTech had a net margin of 55.72% and a trailing twelve-month return on equity of 66.45%. The firm's quarterly revenue was down 43.1% compared to the same quarter last year. During the same quarter in the prior year, the business earned $14.56 EPS.

BioNTech declared a -- dividend on Thursday, April 28th. Shareholders of record on Friday, June 3rd will be paid a dividend of $1.5342 per share on Friday, June 17th. This represents a dividend yield of 1.1%. The ex-dividend date is Thursday, June 2nd.
Read our dividend analysis for BNTX.

33 employees have rated BioNTech Chief Executive Officer Ugur Sahin on Glassdoor.com. Ugur Sahin has an approval rating of 89% among the company's employees. 81.0% of employees surveyed would recommend working at BioNTech to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other BioNTech investors own include Moderna (MRNA), Pfizer (PFE), Inovio Pharmaceuticals (INO), Tesla (TSLA), NVIDIA (NVDA), Novavax (NVAX), Gilead Sciences (GILD), Johnson & Johnson (JNJ), Zoom Video Communications (ZM) and Advanced Micro Devices (AMD).

(BNTX) raised $251 million in an initial public offering on Thursday, October 10th 2019. The company issued 13,200,000 shares at $18.00-$20.00 per share. J.P. Morgan, BofA Merrill Lynch, UBS Investment Bank and SVB Leerink acted as the underwriters for the IPO and Canaccord Genuity, Bryan, Garnier, Berenberg, Wolfe Capital Markets and Advisory, Kempen and Mirae Asset Securities were co-managers.

BioNTech trades on the NASDAQ under the ticker symbol "BNTX."

BioNTech's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Baillie Gifford & Co. (2.99%), Temasek Holdings Private Ltd (1.80%), Primecap Management Co. CA (1.73%), Flossbach Von Storch AG (1.39%), Artisan Partners Limited Partnership (0.92%) and BlackRock Inc. (0.62%).

Shares of BNTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of BNTX stock can currently be purchased for approximately $162.63.

BioNTech (NASDAQ:BNTX) has a market capitalization of $39.47 billion and generates $22.45 billion in revenue each year. The company earns $12.18 billion in net income (profit) each year or $44.26 on an earnings per share basis.

The company employs 3,082 workers across the globe.

BioNTech's mailing address is AN DER GOLDGRUBE 12, MAINZ 2M, 55131. The official website for the company is www.biontech.de. The company can be reached via phone at 49-61-31908-40, via email at investors@biontech.de, or via fax at 49-6131-908-4390.